Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: A randomized placebo‐controlled study

Gonzales, David; Nides, Mitchell; Ferry, Linda Hyder; Kustra, Robert P.; Jamerson, Brenda D.; Segall, Nathan; Herrero, L.; Krishen, Alok; Sweeney, Addison; Buaron, Kathleen S.; Metz, Alan

doi:10.1067/mcp.2001.115750

Cited by 136 publications

(74 citation statements)

References 12 publications

(11 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In nine bupropion effectiveness studies examined, subjects received extensive counselling with seven studies reporting weekly brief (15 minutes or less) face-to-face counselling from research assistants, trial nurses and counsellor/psychologists. [25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40][41][42][43] However, Australian studies have shown that smokers enrolled in smoking cessation pharmacotherapies are unlikely to actively participate in counselling. 44,45 The weight of research suggests that counselling does increase successful quit rates among smokers, therefore, if the additional expenditure is being spent on pharmacotherapies the additional marginal expenditure on telephone counselling may be money well spent.…”

Section: Discussionmentioning

confidence: 99%

Cost effectiveness analysis of smoking cessation interventions

Shearer

Shanahan

2006

Australian and New Zealand Journal of Public Health

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Cost effectiveness analysis of smoking cessation interventions

Shearer

Shanahan

2006

Australian and New Zealand Journal of Public Health

View full text Add to dashboard Cite

“…However, although there exists behavioral and pharmacological treatments designed to promote smoking cessation, the great majority of abstinent smokers relapse after a quit attempt (Balfour and Fagerstrom 1996;Shiffman et al 1998;Fiore et al 2000), and almost all smokers who relapsed after initial cessation pharmacotherapy return to smoking after subsequent quit attempts (Tonnesen et al 1993;Gourlay et al 1995;Gonzales et al 2001). Therefore, the high rates of resumption of smoking after abstinence present a formidable challenge for the treatment of nicotine addiction.…”

Section: Introductionmentioning

confidence: 99%

Cue-induced reinstatement of nicotine-seeking behavior in rats: effect of bupropion, persistence over repeated tests, and its dependence on training dose

et al. 2007

View full text Add to dashboard Cite

Rationale-The motivational effects of nicotine-associated cues have been demonstrated in animal studies. However, it is unknown whether the effectiveness of nicotine cues in reinstating nicotineseeking varies with the extent of prior nicotine self-administration. In addition, the issue of whether bupropion (an FDA-approved smoking cessation medication) interferes with the conditioned incentive of nicotine cues remains to be addressed.Objective-This study determined the relationship of cue-reinstated nicotine-seeking and the levels of prior self-administration and examined the effect of bupropion on cue-induced reinstatement of nicotine-seeking in comparison with that on self-administration. Materials and methods-MaleSprague-Dawley rats were trained in daily 1-h sessions to intravenously self-administer nicotine at different doses (0, 0.015, 0.03, 0.06 mg/kg/infusion) and to associate an auditory/visual cue with each nicotine delivery. After extinction, three reinstatement tests at 15 day intervals were conducted with re-presentation of the cue without nicotine delivery. In separate groups of rats trained with 0.03 mg/kg/infusion nicotine, bupropion (0, 10, 20, 40 mg/kg) was intraperitoneally administered to different groups before the reinstatement and in a withinsubject design before the self-administration tests.Results-Cue-induced reinstatement of active lever responses was observed at all nicotine doses in the first reinstatement test, but at only the two highest doses during the second and third tests. The magnitude of reinstatement was positively correlated with level of prior responding for nicotine. Bupropion pretreatment decreased nicotine self-administration but enhanced cue-reinstated nicotineseeking.Conclusions-These results demonstrate the positive correlation of cue-reinstated nicotineseeking with prior responding for nicotine self-administration and the persistence of the cue effect after taking higher doses of nicotine. The results of pharmacological tests suggest that although it is able to help achieve smoking cessation, bupropion may have little clinical benefit for the prevention of relapse associated with exposure to environmental smoking cues.

show abstract

“…Indeed, the effects of bupropion sustained-release (SR), the only approved non-nicotinic medication, are thought to be mediated by dopaminergic mechanisms such as by blocking the reuptake of dopamine. [20][21][22][23] While several placebocontrolled trials of bupropion SR for smoking cessation have demonstrated its efficacy to promote smoking cessation 21,24,25 and a recent field trial has also shown the effectiveness of bupropion in actual practice, 26,27 only a minority of smokers treated with bupropion SR quit smoking for clinically meaningful periods (approximately 25-30% at 1 year follow-up).…”

Section: Introductionmentioning

confidence: 99%

Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR

et al. 2004

View full text Add to dashboard Cite

The A1 allele of the dopamine D2 receptor gene (DRD2) is associated with a reduced number of dopamine binding sites in the brain and with the increased likelihood of substance abuse and addictive behavior. In a study of smokers enrolled in an open-label, randomized effectiveness trial, we investigated whether variants in the DRD2 receptor gene are associated with smoking cessation outcomes following treatment with a combination of bupropion SR and behavioral counseling. Adherence to treatment and pointprevalent smoking status were assessed at 3 and 12 months, respectively, following a target quit date. Compared to women who carry both A2 alleles, women with at least one A1 allele were more likely to report having stopped taking bupropion due to medication side effects (odds ratio (OR) ¼ 1.91, 95% confidence interval (CI) ¼ 1.01-3.60; Po0.04) and at 12 months were somewhat more likely to report smoking (OR ¼ 0.76, 95% CI ¼ 0.56-1.03; Po0.076). Significant associations or trends were not observed in men. In women, individual variability in responsiveness to bupropion-based treatment may be partially due to differences in genetic variants influencing dopamine receptor function. INTRODUCTIONTobacco use remains the major preventable cause of premature disability and death in developed countries. Despite best efforts to date, 46 million people still smoke in the United States, and over 440 000 people die each year from tobaccorelated illness; the estimated smoking-related cost to the economy is $157 billion annually.1 Effective pharmacologic interventions for smoking cessation include several forms of nicotine replacement and the use of the antidepressant medication, bupropion.2 Despite treatment advances, smoking relapse after successful intervention for smoking cessation occurs in 70 to 80% of patients within 12 months. [3][4][5] Still to be determined is why some people remain nonsmokers after pharmacologic intervention and others do not.The dopaminergic mesocorticolimbic pathway in the brain is thought to play an important role in tobacco and nicotine addiction. [6][7][8] The TaqIA polymorphism of the dopamine D2 receptor gene (DRD2) results from a C/T

show abstract

Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: A randomized placebo‐controlled study

Abstract: Bupropion SR is an effective medication for retreatment of smokers who have used bupropion SR previously.

Cited by 136 publications

References 12 publications

Cost effectiveness analysis of smoking cessation interventions

Cost effectiveness analysis of smoking cessation interventions

Cue-induced reinstatement of nicotine-seeking behavior in rats: effect of bupropion, persistence over repeated tests, and its dependence on training dose

Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR

Contact Info

Product

Resources

About